ISNARDI V.
- Country
- France
- Department
- Rhone-Alpe
Research Overview
Data & Insights
Has run more than one trial at 0 of 2 partner sites.
Specializations
Molecularly Targeted Solid Tumors
The investigator concentrates on advanced solid neoplasms defined by actionable genomic alterations.
- MTAP‑deleted tumors
- KRAS G12C‑mutant cancers
- HER2‑mutant or amplified malignancies
- ALK‑rearranged lung cancer
- FGFR‑altered cholangiocarcinoma
Research is conducted at Centre Leon Berard in Lyon.
Immuno‑oncology and Checkpoint Modulation
Focus on therapies that engage the immune system to eradicate malignant cells.
- PD‑L1 checkpoint inhibition
- CTLA‑4 blockade
- HPV‑associated head‑and‑neck cancers
- T‑cell engaging bispecific antibodies
- CAR‑T strategies for B‑cell malignancies
Clinical activity is evaluated across metastatic disease settings.
Hematologic Malignancies and Cellular Therapies
Dedicated to blood‑derived cancers and innovative cellular approaches.
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Chronic Lymphocytic Leukemia
- Multiple Myeloma
- Diffuse Large B‑Cell Lymphoma
Trials integrate molecular profiling for risk‑adapted treatment.
Rare and Pediatric Oncology
Addresses low‑incidence neoplasms and childhood malignancies.
- Ewing sarcoma
- Alveolar rhabdomyosarcoma
- Diffuse Intrinsic Pontine Glioma
- Neuroblastoma
- Chordoma
Collaboration leverages specialized expertise at the regional oncology center.
Biomarker‑Driven Precision Oncology
Leverages predictive biomarkers to tailor therapeutic regimens.
- Microsatellite Instability‑High (MSI‑H)
- Tumor Mutational Burden‑High (TMB‑H)
- Mismatch Repair‑deficient (dMMR)
- PD‑L1 expression
- BRCA‑mutated tumors
Biomarker assessment supports enrollment in genotype‑selected trials.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.